12-9908-41
antibody from Invitrogen Antibodies
Targeting: TNFRSF10B
CD262, DR5, KILLER, TRAIL-R2, TRAILR2, TRICK2A, TRICKB
Antibody data
- Antibody Data
- Antigen structure
- References [41]
- Comments [0]
- Validations
- Flow cytometry [1]
- Other assay [8]
Submit
Validation data
Reference
Comment
Report error
- Product number
- 12-9908-41 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), PE, eBioscience™
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells. Applications Reported: The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis. Applications Tested: This DJR2-4 (a.k.a. 7-8) antibody has been pre-titrated and tested by flow cytometric analysis of normal human peripheral blood cells. This can be used at 5 µL (0.25 µg) per test. A test is defined as the amount (µg) of antibody that will stain a cell sample in a final volume of 100 µL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. Excitation: 488-561 nm; Emission: 578 nm; Laser: Blue Laser, Green Laser, Yellow-Green Laser. Filtration: 0.2 µm post-manufacturing filtered.
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Yellow dye
- Isotype
- IgG
- Antibody clone number
- DJR2-4 (7-8)
- Vial size
- 25 Tests
- Concentration
- 5 µL/Test
- Storage
- 4° C, store in dark, DO NOT FREEZE!
Submitted references Doxorubicin sensitizes breast cancer cells to natural killer cells in connection with increased Fas receptors.
Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells.
Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1).
The metabolism of cells regulates their sensitivity to NK cells depending on p53 status.
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models.
YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells.
Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking.
Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and γ-irradiation in human glioblastoma cells.
Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways.
Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages.
Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro.
Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.
The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer.
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.
A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.
Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling.
Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation.
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death.
Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
Sawasdee N, Wattanapanitch M, Thongsin N, Phanthaphol N, Chiawpanit C, Thuwajit C, Yenchitsomanus PT, Panya A
International journal of molecular medicine 2022 Mar;49(3)
International journal of molecular medicine 2022 Mar;49(3)
Genistein Sensitizes Human Cholangiocarcinoma Cell Lines to Be Susceptible to Natural Killer Cells.
Chiawpanit C, Panwong S, Sawasdee N, Yenchitsomanus PT, Panya A
Biology 2022 Jul 23;11(8)
Biology 2022 Jul 23;11(8)
Metformin sensitizes leukemic cells to cytotoxic lymphocytes by increasing expression of intercellular adhesion molecule-1 (ICAM-1).
Allende-Vega N, Marco Brualla J, Falvo P, Alexia C, Constantinides M, Fayd'herbe de Maudave A, Coenon L, Gitenay D, Mitola G, Massa P, Orecchioni S, Bertolini F, Marzo I, Anel A, Villalba M
Scientific reports 2022 Jan 25;12(1):1341
Scientific reports 2022 Jan 25;12(1):1341
The metabolism of cells regulates their sensitivity to NK cells depending on p53 status.
Belkahla S, Brualla JM, Fayd'herbe de Maudave A, Falvo P, Allende-Vega N, Constantinides M, Khan AUH, Coenon L, Alexia C, Mitola G, Massa P, Orecchioni S, Bertolini F, Mnif W, Hernandez J, Anel A, Villalba M
Scientific reports 2022 Feb 25;12(1):3234
Scientific reports 2022 Feb 25;12(1):3234
Death agonist antibody against TRAILR2/DR5/TNFRSF10B enhances birinapant anti-tumor activity in HPV-positive head and neck squamous cell carcinomas.
An Y, Jeon J, Sun L, Derakhshan A, Chen J, Carlson S, Cheng H, Silvin C, Yang X, Van Waes C, Chen Z
Scientific reports 2021 Mar 18;11(1):6392
Scientific reports 2021 Mar 18;11(1):6392
RALB GTPase: a critical regulator of DR5 expression and TRAIL sensitivity in KRAS mutant colorectal cancer.
Khawaja H, Campbell A, Roberts JZ, Javadi A, O'Reilly P, McArt D, Allen WL, Majkut J, Rehm M, Bardelli A, Di Nicolantonio F, Scott CJ, Kennedy R, Vitale N, Harrison T, Sansom OJ, Longley DB, Evergren E, Van Schaeybroeck S
Cell death & disease 2020 Oct 29;11(10):930
Cell death & disease 2020 Oct 29;11(10):930
DR5-targeted, chemotherapeutic drug-loaded nanoparticles induce apoptosis and tumor regression in pancreatic cancer in vivo models.
Johnston MC, Nicoll JA, Redmond KM, Smyth P, Greene MK, McDaid WJ, Chan DKW, Crawford N, Stott KJ, Fox JP, Straubinger NL, Roche S, Clynes M, Straubinger RM, Longley DB, Scott CJ
Journal of controlled release : official journal of the Controlled Release Society 2020 Aug 10;324:610-619
Journal of controlled release : official journal of the Controlled Release Society 2020 Aug 10;324:610-619
YIPF2 promotes chemotherapeutic agent-mediated apoptosis via enhancing TNFRSF10B recycling to plasma membrane in non-small cell lung cancer cells.
Wang Y, Guo S, Li D, Tang Y, Li L, Su L, Liu X
Cell death & disease 2020 Apr 17;11(4):242
Cell death & disease 2020 Apr 17;11(4):242
Systematic genetic mapping of necroptosis identifies SLC39A7 as modulator of death receptor trafficking.
Fauster A, Rebsamen M, Willmann KL, César-Razquin A, Girardi E, Bigenzahn JW, Schischlik F, Scorzoni S, Bruckner M, Konecka J, Hörmann K, Heinz LX, Boztug K, Superti-Furga G
Cell death and differentiation 2019 Jun;26(6):1138-1155
Cell death and differentiation 2019 Jun;26(6):1138-1155
Inhibition of ATM kinase upregulates levels of cell death induced by cannabidiol and γ-irradiation in human glioblastoma cells.
Ivanov VN, Wu J, Wang TJC, Hei TK
Oncotarget 2019 Jan 25;10(8):825-846
Oncotarget 2019 Jan 25;10(8):825-846
Regulation of human glioblastoma cell death by combined treatment of cannabidiol, γ-radiation and small molecule inhibitors of cell signaling pathways.
Ivanov VN, Wu J, Hei TK
Oncotarget 2017 Sep 26;8(43):74068-74095
Oncotarget 2017 Sep 26;8(43):74068-74095
Dual Agonist Surrobody Simultaneously Activates Death Receptors DR4 and DR5 to Induce Cancer Cell Death.
Milutinovic S, Kashyap AK, Yanagi T, Wimer C, Zhou S, O'Neil R, Kurtzman AL, Faynboym A, Xu L, Hannum CH, Diaz PW, Matsuzawa S, Horowitz M, Horowitz L, Bhatt RR, Reed JC
Molecular cancer therapeutics 2016 Jan;15(1):114-24
Molecular cancer therapeutics 2016 Jan;15(1):114-24
Gene Expression Ratios Lead to Accurate and Translatable Predictors of DR5 Agonism across Multiple Tumor Lineages.
Reddy A, Growney JD, Wilson NS, Emery CM, Johnson JA, Ward R, Monaco KA, Korn J, Monahan JE, Stump MD, Mapa FA, Wilson CJ, Steiger J, Ledell J, Rickles RJ, Myer VE, Ettenberg SA, Schlegel R, Sellers WR, Huet HA, Lehár J
PloS one 2015;10(9):e0138486
PloS one 2015;10(9):e0138486
Potential Therapeutic Effect of Natural Killer Cells on Doxorubicin-Resistant Breast Cancer Cells In Vitro.
Hwang MH, Li XJ, Kim JE, Jeong SY, Lee SW, Lee J, Ahn BC
PloS one 2015;10(8):e0136209
PloS one 2015;10(8):e0136209
Combination of systemic chemotherapy with local stem cell delivered S-TRAIL in resected brain tumors.
Redjal N, Zhu Y, Shah K
Stem cells (Dayton, Ohio) 2015 Jan;33(1):101-10
Stem cells (Dayton, Ohio) 2015 Jan;33(1):101-10
Combining an Aurora Kinase Inhibitor and a Death Receptor Ligand/Agonist Antibody Triggers Apoptosis in Melanoma Cells and Prevents Tumor Growth in Preclinical Mouse Models.
Liu Y, Hawkins OE, Vilgelm AE, Pawlikowski JS, Ecsedy JA, Sosman JA, Kelley MC, Richmond A
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 1;21(23):5338-48
Clinical cancer research : an official journal of the American Association for Cancer Research 2015 Dec 1;21(23):5338-48
Increased growth-inhibitory and cytotoxic activity of arsenic trioxide in head and neck carcinoma cells with functional p53 deficiency and resistance to EGFR blockade.
Boyko-Fabian M, Niehr F, Distel L, Budach V, Tinhofer I
PloS one 2014;9(6):e98867
PloS one 2014;9(6):e98867
TRAIL-mediated apoptosis in breast cancer cells cultured as 3D spheroids.
Chandrasekaran S, Marshall JR, Messing JA, Hsu JW, King MR
PloS one 2014;9(10):e111487
PloS one 2014;9(10):e111487
The oncogene metadherin modulates the apoptotic pathway based on the tumor necrosis factor superfamily member TRAIL (Tumor Necrosis Factor-related Apoptosis-inducing Ligand) in breast cancer.
Zhang N, Wang X, Huo Q, Li X, Wang H, Schneider P, Hu G, Yang Q
The Journal of biological chemistry 2013 Mar 29;288(13):9396-407
The Journal of biological chemistry 2013 Mar 29;288(13):9396-407
Real-time imaging of the dynamics of death receptors and therapeutics that overcome TRAIL resistance in tumors.
Bagci-Onder T, Agarwal A, Flusberg D, Wanningen S, Sorger P, Shah K
Oncogene 2013 Jun 6;32(23):2818-27
Oncogene 2013 Jun 6;32(23):2818-27
Induction of proapoptotic antibodies to triple-negative breast cancer by vaccination with TRAIL death receptor DR5 DNA.
Piechocki MP, Wu GS, Jones RF, Jacob JB, Gibson H, Ethier SP, Abrams J, Yagita H, Venuprasad K, Wei WZ
International journal of cancer 2012 Dec 1;131(11):2562-72
International journal of cancer 2012 Dec 1;131(11):2562-72
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.
Woldemichael GM, Turbyville TJ, Vasselli JR, Linehan WM, McMahon JB
Neoplasia (New York, N.Y.) 2012 Aug;14(8):771-7
Neoplasia (New York, N.Y.) 2012 Aug;14(8):771-7
Lack of a functional VHL gene product sensitizes renal cell carcinoma cells to the apoptotic effects of the protein synthesis inhibitor verrucarin A.
Woldemichael GM, Turbyville TJ, Vasselli JR, Linehan WM, McMahon JB
Neoplasia (New York, N.Y.) 2012 Aug;14(8):771-7
Neoplasia (New York, N.Y.) 2012 Aug;14(8):771-7
A whole-genome RNAi screen identifies an 8q22 gene cluster that inhibits death receptor-mediated apoptosis.
Dompe N, Rivers CS, Li L, Cordes S, Schwickart M, Punnoose EA, Amler L, Seshagiri S, Tang J, Modrusan Z, Davis DP
Proceedings of the National Academy of Sciences of the United States of America 2011 Oct 25;108(43):E943-51
Proceedings of the National Academy of Sciences of the United States of America 2011 Oct 25;108(43):E943-51
Molecular identification of an MHC-independent ligand recognized by a human {alpha}/{beta} T-cell receptor.
Hanada K, Wang QJ, Inozume T, Yang JC
Blood 2011 May 5;117(18):4816-25
Blood 2011 May 5;117(18):4816-25
Measurement of conatumumab-induced apoptotic activity in tumors by fine needle aspirate sampling.
Zoog SJ, Ma CY, Kaplan-Lefko PJ, Hawkins JM, Moriguchi J, Zhou L, Pan Y, Hsu CP, Friberg G, Herbst R, Hill J, Juan G
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2010 Sep;77(9):849-60
Cytometry. Part A : the journal of the International Society for Analytical Cytology 2010 Sep;77(9):849-60
Inability of plasmacytoid dendritic cells to directly lyse HIV-infected autologous CD4+ T cells despite induction of tumor necrosis factor-related apoptosis-inducing ligand.
Chehimi J, Papasavvas E, Tomescu C, Gekonge B, Abdulhaqq S, Raymond A, Hancock A, Vinekar K, Carty C, Reynolds G, Pistilli M, Mounzer K, Kostman J, Montaner LJ
Journal of virology 2010 Mar;84(6):2762-73
Journal of virology 2010 Mar;84(6):2762-73
Predominant antitumor effects by fully human anti-TRAIL-receptor 2 (DR5) monoclonal antibodies in human glioma cells in vitro and in vivo.
Nagane M, Shimizu S, Mori E, Kataoka S, Shiokawa Y
Neuro-oncology 2010 Jul;12(7):687-700
Neuro-oncology 2010 Jul;12(7):687-700
c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.
Fu L, Lin YD, Elrod HA, Yue P, Oh Y, Li B, Tao H, Chen GZ, Shin DM, Khuri FR, Sun SY
Molecular cancer 2010 Dec 20;9:315
Molecular cancer 2010 Dec 20;9:315
TRAIL death receptor-4, decoy receptor-1 and decoy receptor-2 expression on CD8+ T cells correlate with the disease severity in patients with rheumatoid arthritis.
Bisgin A, Terzioglu E, Aydin C, Yoldas B, Yazisiz V, Balci N, Bagci H, Gorczynski RM, Akdis CA, Sanlioglu S
BMC musculoskeletal disorders 2010 Aug 27;11:192
BMC musculoskeletal disorders 2010 Aug 27;11:192
Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition.
Ames E, Hallett WH, Murphy WJ
Clinical and experimental immunology 2009 Mar;155(3):504-13
Clinical and experimental immunology 2009 Mar;155(3):504-13
ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis.
Song JH, Kandasamy K, Kraft AS
The Journal of biological chemistry 2008 Sep 5;283(36):25003-13
The Journal of biological chemistry 2008 Sep 5;283(36):25003-13
Coupling of endoplasmic reticulum stress to CDDO-Me-induced up-regulation of death receptor 5 via a CHOP-dependent mechanism involving JNK activation.
Zou W, Yue P, Khuri FR, Sun SY
Cancer research 2008 Sep 15;68(18):7484-92
Cancer research 2008 Sep 15;68(18):7484-92
CAAT/enhancer binding protein homologous protein-dependent death receptor 5 induction is a major component of SHetA2-induced apoptosis in lung cancer cells.
Lin YD, Chen S, Yue P, Zou W, Benbrook DM, Liu S, Le TC, Berlin KD, Khuri FR, Sun SY
Cancer research 2008 Jul 1;68(13):5335-44
Cancer research 2008 Jul 1;68(13):5335-44
The proteasome inhibitor PS-341 (bortezomib) up-regulates DR5 expression leading to induction of apoptosis and enhancement of TRAIL-induced apoptosis despite up-regulation of c-FLIP and survivin expression in human NSCLC cells.
Liu X, Yue P, Chen S, Hu L, Lonial S, Khuri FR, Sun SY
Cancer research 2007 May 15;67(10):4981-8
Cancer research 2007 May 15;67(10):4981-8
The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.
Sun SY, Liu X, Zou W, Yue P, Marcus AI, Khuri FR
The Journal of biological chemistry 2007 Jun 29;282(26):18800-9
The Journal of biological chemistry 2007 Jun 29;282(26):18800-9
Enhancement of Ad5-TRAIL cytotoxicity against renal cell carcinoma with histone deacetylase inhibitors.
VanOosten RL, Earel JK Jr, Griffith TS
Cancer gene therapy 2006 Jun;13(6):628-32
Cancer gene therapy 2006 Jun;13(6):628-32
Histone deacetylase inhibitors modulate the sensitivity of tumor necrosis factor-related apoptosis-inducing ligand-resistant bladder tumor cells.
Earel JK Jr, VanOosten RL, Griffith TS
Cancer research 2006 Jan 1;66(1):499-507
Cancer research 2006 Jan 1;66(1):499-507
c-FLIP inhibits chemotherapy-induced colorectal cancer cell death.
Longley DB, Wilson TR, McEwan M, Allen WL, McDermott U, Galligan L, Johnston PG
Oncogene 2006 Feb 9;25(6):838-48
Oncogene 2006 Feb 9;25(6):838-48
Synthetic triterpenoids cooperate with tumor necrosis factor-related apoptosis-inducing ligand to induce apoptosis of breast cancer cells.
Hyer ML, Croxton R, Krajewska M, Krajewski S, Kress CL, Lu M, Suh N, Sporn MB, Cryns VL, Zapata JM, Reed JC
Cancer research 2005 Jun 1;65(11):4799-808
Cancer research 2005 Jun 1;65(11):4799-808
c-Jun NH2-terminal kinase-mediated up-regulation of death receptor 5 contributes to induction of apoptosis by the novel synthetic triterpenoid methyl-2-cyano-3,12-dioxooleana-1, 9-dien-28-oate in human lung cancer cells.
Zou W, Liu X, Yue P, Zhou Z, Sporn MB, Lotan R, Khuri FR, Sun SY
Cancer research 2004 Oct 15;64(20):7570-8
Cancer research 2004 Oct 15;64(20):7570-8
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Surface staining of human CD262-transfected cells with Mouse IgG1 K Isotype Control PE (Product # 12-4714-81) (open histogram) or Anti-Human CD262 (DR5) PE (filled histogram). Total viable cells were used for analysis.
- Conjugate
- Yellow dye
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- NULL
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 BT20 and MCF7 spheroids have a lower expression of death receptors. (A) Confocal micrographs of BT20 and MCF7 cells cultured as 3D spheroids and 2D monolayer stained with antibodies against DR4 (red), DR5 (red) and EpCAM (green). (Scale bar = 20 um) (B) Flow cytometry histograms comparing DR4 and DR5 expression in BT20 and MCF7 spheroids and monolayer. (C) Western blot analysis of total DR4 and DR5 expression in cell lysates from BT20 and MCF7 spheroids and monolayer.
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 YIPF2 enhances TNFRSF10B recycling to plasma membrane. a Overexpression of YIPF2 in A549 and H1792 cells. The surface expression of TNFRSF10B was confirmed by flow cytometry analyses. b Knockdown of YIPF2 expression by YIPF2-1 and YIPF2-2 siRNA in A549 cells. The surface expression of TNFRSF10B was confirmed by flow cytometry analyses. c Relative RT-qPCR analyses of YIPF2 and TNFRSF10B mRNA levels after YIPF2 overexpression in H1792 (left) and H1299 (right) cells ( n = 3). d Relative RT-qPCR analyses of YIPF2 and TNFRSF10B mRNA levels after YIPF2 knocking down in H1792 (left) and H1299 (right) cells ( n = 3). e Left: Overexpression of YIPF2 in H1299 cells in the presence or absence of cycloheximide (CHX) at 10 mug/mL for the indicated times (0, 4, 8 and 12 h). Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B and ACTB. Right: The band intensity of TNFRSF10B was quantified by ImageJ software and plotted. This experiment was repeated three times independently with similar results. f Left: Knockdown of YIPF2 expression by YIPF2-1 siRNA in A549 cells in the presence or absence of cycloheximide (CHX) at 10 mug/mL for the indicated times (0, 4, 8 and 12 h). Cell lysates were analyzed by Western blotting with antibodies against YIPF2, TNFRSF10B and ACTB. Right: The band intensity of TNFRSF10B was quantified by ImageJ software and plotted. This experiment was repeated three times independently with similar results. (mean +- SEM, n = 3 inde
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 RALB silencing regulates DR5 expression levels. A Top Left: HCT116 cells were transfected with 10 nM SC, siRALA, siRALB or siRALGDS for 24 h, following which cells were harvested for protein extraction. Protein was subsequently analysed using a human apoptosis array. Densitometry was performed on the array panels using ImageJ software, and results for DR4, DR5, Fas/CD95, FADD and TNFR1/TNFRSF1A are shown. Top right: PARP, DR5, DR4, FADD, XIAP, Bcl-xL, RALA and RALB levels in CRC cells following RALA, RALB and RALGDS silencing for the indicated times. Bottom left: Wheat germ agglutinin (WGA), a lectin that binds N -acetylglucosamine post-translational modifications on membrane receptors, was used as a plasma membrane marker. Fixed cells were stained with Alexa488-WGA prior to permeabilisation to minimise the staining of glycosylated proteins in the Golgi apparatus. A single confocal image was collected of the Alexa488-WGA stained membrane (green) alongside immunostained endogenous DR5 (red). Laser settings were kept constant between the samples to enable the comparison of membrane-associated DR5 staining in control (SC) and siRALB-treated cells. Bottom right: >20 cells were scored for intensity in ImageJ. The intensity was normalised to cellular area and plotted. The data are representative of three independent experiments. B CRC cells were transfected with 10 nM SC or siRALB for 24 h and DR5 cell-membrane expression was assessed by flow cytometry using a DR5-specific p
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 3 Protein expression of FADD, IAPs, and TRAILR2/DR5 in HPV(+) HNSCC cell lines. ( A ). Protein expression from whole cell lysates of HOK and a panel of HPV(+) HNSCC cell lines were examined by Western blot. Protein expression was quantified by comparison to HOK and actin as a loading control. ( B ) UM-SCC-47 and UPCI-SCC-90 cells were stained with fluorescent conjugated anti-TRAILR2/DR5 antibody and Zombie-violet for viability. The x-axis represents TRAILR2/DR5 fluorescent intensity, and the y-axis represents cell count. Percentages of TRAILR2/DR5 positivity among live cells for each cell line are represented and compared with the negative controls of unstained cells. ( C ) TRAILR2/DR5 staining of Jurkat cells was served as a positive control for data presented by ( B ), and the unstained cells served as the negative control. ( D ) There was no statistical difference in the percentages of TRAILR2/DR5 positive staining cells between the two HNSCC cell lines. The data are presented by six replicates from two independent experiments. * or ** indicates Student''s t test, p < 0.05 or 0.01.
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 COX-2 inhibitor treatment upregulates the expression of DR4 and DR5 in BT20 and MCF7 spheroids. (A) Flow cytometry histograms showing the effect of 100 uM NS-398 treatment on death receptor expression in BT20 and MCF7 cells cultured as spheroids. (B) Western blot analysis of whole cell lysates from untreated and NS-398 treated BT20 and MCF7 spheroids for DR4 and DR5 expression. (C) Flow cytometry scatter plots showing the effect of NS-398 treatment on the prevalence of CD44 hi CD24 lo population in BT20 and MCF7 cells cultured as spheroids.
- Conjugate
- Yellow dye
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 8 COX-2 knockdown reverses TRAIL-resistance in MCF7 spheroid and monolayer cells. (A) qPCR and western blot data showing the relative expression of COX-2 gene (n = 3) and COX-2 protein in control siRNA and COX-2 siRNA transfected MCF7 cells. (B) Flow cytometry histograms and (C) western blot analysis comparing the expression of DR4 in MCF7 cells transfected with control siRNA and COX-2 siRNA cultured as monolayer and spheroids. (D) Bright field images and (E) MTT assay results (n = 5) quantifying the effect of 200 ng/mL of TRAIL in control siRNA and COX-2 siRNA transfected cells cultured as monolayer and spheroids.
- Conjugate
- Yellow dye